National Human Genome Research Institute; Notice of Closed Meeting, 19329 [2015-08213]

Download as PDF Federal Register / Vol. 80, No. 69 / Friday, April 10, 2015 / Notices individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel. Date: May 7, 2015. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Peter Zelazowski, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892–9304, (301) 435–6902, peter.zelazowski@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: April 7, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–08294 Filed 4–9–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Date: Center for Inherited Disease Research Access Committee. Date: April 23, 2015. Time: 11:30 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Telephone Conference Call). VerDate Sep<11>2014 20:09 Apr 09, 2015 Jkt 235001 Contact Person: Camilla E. Day, Ph.D., Scientific Review Officer, CIDR, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Suite 4075, Bethesda, MD 20892, 301–402–8837, camilla.day@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: April 6, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–08213 Filed 4–9–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. SUMMARY: Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen Description of Technology: Scientists at the National Institutes of Health have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, nonHodgkin’s lymphoma, and chronic lymphocytic leukemia. The anti-CD70 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 19329 CARs are hybrid proteins consisting of a receptor portion that recognizes CD70 antigen, and intracellular T cell signaling domains selected to optimally activate the CAR expressing T cells. Genetically engineered T cells that express this CARs will bind to CD70 on the cancer cells and will be activated to induce an immune response that promotes robust tumor cell elimination when infused into cancer patients. This technology can rapidly generate a vigorous T-cell response from the patient’s own blood, targeting CD70 expressing cancer cells, and potentially induce tumor rejection. Potential Commercial Applications: • Immunotherapeutics to treat cancers that overexpress CD70, such as renal cell carcinoma, glioblastoma, nonHodgkin’s lymphoma, and chronic lymphocytic leukemia. • A personalized cancer treatment strategy for patients whose tumor cells express CD70 whereby the patient’s own T cells are isolated, engineered to express the anti-CD70 CARs, and reinfused into the same patient to attack the tumor(s). Competitive Advantages: • CD70-specific CARs expressed on T cells will increase the likelihood of successful targeted therapy. • CAR–T cells target only CD70 expressing cells and thus may generate fewer side effects than other cancer treatment approaches. • With the advent of Provenge(R), and Yervoy(R), immunotherapy is now more widely accepted as a viable cancer treatment option. • T-cell transfer can provide much larger numbers of anti-tumor immune cells compared to other approaches such as vaccines. Development Stage: • Early-stage. • In vitro data available. • In vivo data available (animal). Inventors: Qiong J. Wang, Zhiya Yu, James C. Yang (all of NCI). Publication: Wang QJ, et al. Distinctive features of the differentiated phenotype and infiltration of tumorreactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012 Dec 1; 72(23):6119–29. [PMID 23071066] Intellectual Property: HHS Reference No. E–021–2015/0—U.S. Patent Application No. 62/088,882 filed 08 Dec 2014. Licensing Contact: Whitney A. Hastings, Ph.D.; 301–451–7337; hastingw@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or E:\FR\FM\10APN1.SGM 10APN1

Agencies

[Federal Register Volume 80, Number 69 (Friday, April 10, 2015)]
[Notices]
[Page 19329]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-08213]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Date: Center for Inherited Disease Research 
Access Committee.
    Date: April 23, 2015.
    Time: 11:30 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5635 Fishers Lane, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Camilla E. Day, Ph.D., Scientific Review 
Officer, CIDR, National Human Genome Research Institute, National 
Institutes of Health, 5635 Fishers Lane, Suite 4075, Bethesda, MD 
20892, 301-402-8837, camilla.day@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: April 6, 2015.
David Clary,
Program Analyst,
    Office of Federal Advisory Committee Policy.
[FR Doc. 2015-08213 Filed 4-9-15; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.